Zevra Therapeutics issues letter to stockholders on recent accomplishments

Zevra Therapeutics announced that Neil McFarlane, Zevra’s President and Chief Executive Officer, has issued a Letter to Stockholders providing a review of key accomplishments and outlook for 2024. “Our Company continues to work through a period of significant growth and transformation with the addition of meaningful new skills and capabilities from the strengths of three companies that have now come together to become One Zevra. Today, I am pleased to share with you a summary of our recent key accomplishments and the reasons for my optimism for 2024 and beyond. We are Building a High-Performance Team… We’ve Made Significant Progress Advancing our Rare Disease Portfolio… We have a Foundation of Financial Strength… We’re Committed to Governance Best Practices… We are Optimistic about Our Future. Bringing it all together, I am confident the opportunities we have in front of us have the potential to deliver meaningful stockholder value… The pace of Zevra’s transformation has been tremendous, and I am proud of how much progress we have made. However, there is much more to do. From the combined strength of three teams with diverse experiences and backgrounds, we have become One Zevra, fully focused and dedicated to our mission of bringing life-changing therapeutics to people living with rare disease.”